Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 1/2001

01-01-2001 | Review Article

Bodyweight Gain with Atypical Antipsychotic

A Comparative Review

Author: Professor Tilman Wetterling

Published in: Drug Safety | Issue 1/2001

Login to get access

Abstract

The atypical antipsychotics have been shown to have superior efficacy compared with typical antipsychotics such as haloperidol, particularly in the treatment of negative symptoms of schizophrenia. Furthermore, they induce less extrapyramidal effects. However, following clinical use, marked bodyweight gain has been frequently observed with some of the atypical antipsychotic drugs.
In order to examine and compare the frequency, amount and conditions of bodyweight gain during treatment with atypical antipsychotics, studies concerning bodyweight gain with these agents were identified through a MEDLINE search from 1966 to March 2000.
Although comparison is limited by the different designs and recruitment procedures of the reviewed studies, the available data support the notion that the frequency as well as the amount of bodyweight gain is high in patients treated with olanzapine (average bodyweight gain 2.3 kg/month), clozapine (1.7 kg/month), quetiapine (1.8 kg/month), and possibly also zotepine (2.3 kg/month). Moderate changes in bodyweight have been observed in the treatment with risperidone (average bodyweight gain 1.0 kg/month). Ziprasidone seems to induce only slight bodyweight changes (0.8 kg/month). Bodyweight gain most frequently occurs in the first 12 weeks of treatment. Patients who were underweight at the beginning of treatment are at highest risk of gaining bodyweight.
The underlying pathomechanism still remains largely unclear. The relative receptor affinities of the atypical antipsychotics for histamine H1 receptors as well as the ratio of their affinity for serotonin 5-HT2 and dopamine D2 receptors appear to be the most robust correlate of bodyweight gain. Furthermore, the induction of leptin secretion may have an important impact on bodyweight gain in patients treated with atypical antipsychotics.
Although many questions concerning the pathogenesis of bodyweight gain remain unresolved, this adverse effect has to be taken into consideration when prescribing the atypical antipsychotics, particularly in view its affect on compliance during long term treatment and the long term effects of obesity on mortality and morbidity.
Literature
1.
Kane JM. What makes an antipsychotic ‘atypical’? CNS Drugs 1997; 7: 947–8CrossRef
2.
Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999; 60Suppl. 10: S31–S41
3.
Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996; 124: 2–34PubMedCrossRef
4.
Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57–73PubMedCrossRef
5.
Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics. Neuropsychopharmacology 1998; 18: 63–101PubMedCrossRef
6.
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11): 1686–96PubMed
7.
Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1985; 499: 203–15CrossRef
8.
Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463–72PubMedCrossRef
9.
Wetterling T, Müssigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19(4): 316–21PubMedCrossRef
10.
Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6): 358–63PubMedCrossRef
11.
Allison DB, Fontaine KR, Heo M, et al. The distribution of Body Mass Index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60(4): 215–20PubMedCrossRef
12.
Lamperti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149(5): 689–90
13.
Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214–7PubMedCrossRef
14.
Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156(2): 312–4PubMed
15.
Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155(4): 499–504PubMed
16.
Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153(6): 817–9PubMed
17.
John JP, Chengappa KN, Baker RW, et al. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995; 7(3): 119–25PubMedCrossRef
18.
Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149(1): 68–72PubMed
19.
Briffa D, Meehan T. Weight changes during clozapine treatment. Aust N Z J Psychiatry 1998; 32(5): 718–21PubMedCrossRef
20.
Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5: 437–40PubMed
21.
Jalenques I, Coudert AJ. Clozapine et schizophrenies resistantes. Encephale 1994; 20(6): 767–75PubMed
22.
Spivak B, Musin E, Mester R, et al. The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: clozapine versus classical antipsychotic agents. Int Clin Psychopharmacol 1999; 14(4): 229–32PubMedCrossRef
23.
Leppig M, Bosch B, Naber D, et al. Clozapine in the treatment of 121 out-patients. Psychopharmacology (Berl) 1989; 99Suppl.: S77–S79CrossRef
24.
Povlsen UU, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176–85CrossRef
25.
Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156(5): 702–9PubMed
26.
Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124: 159–67CrossRef
27.
Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schzoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65PubMed
28.
Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Br J Psychiatry 1999; 174: 15–22PubMedCrossRef
29.
Conley RR, Mahmoud R, the Risperidone study group. Risperidone versus olanzapine in patients with schizophrenic and schizoaffective psychosis [oral presentation]. US Psychiatric and Mental Health Congress; 1999 Nov 11-14; Altanta
30.
Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60(11): 767–70PubMedCrossRef
31.
McElroy SL, Frye M, Denicoff K, et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998; 49(2): 119–22PubMedCrossRef
32.
Gupta S, Droney T, Al-Samarrai S, et al. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999; 19(3): 273–5PubMedCrossRef
33.
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18PubMedCrossRef
34.
Beasley Jr CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58Suppl. 10: S13–S17
35.
Borison R, Arvanitis LA, Miller BG, et al. USS ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16(2): 158–69PubMedCrossRef
36.
Copolov DL, Link CGG, Kowalcyk B. A comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105PubMedCrossRef
37.
Peukens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265–73CrossRef
38.
Arivanitis LA, Miller BG, and the Seroquel trial 13 study group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: Acomparison with haloperidol and placebo. Biol Psychiatry 1997; 42(4): 233–46CrossRef
39.
Small JG, Hirsch SR, Arvantis LA, et al. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997; 54(6): 549–57PubMedCrossRef
40.
King DJ, Link CGG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 137(2): 139–46PubMedCrossRef
41.
Emsley RA, Ranwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demostrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000, 15: 121–31PubMedCrossRef
42.
Peukens J, Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712–26CrossRef
43.
Anderson C, Clark WR, True J, et al. Risperidone, a novel antipsychotic, and weight change [letter]. Pharmacotherapy 1993; 13: 292
44.
Höyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395–402PubMedCrossRef
45.
Claus A, Bollen J, De-Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305PubMedCrossRef
46.
Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 1996; 32(4): 721–9PubMed
47.
Csernansky J, Okamoto A, Brecher M. Risperidone vs. haloperidol as relapse prevention in schizophrenic and schizoaffective disorders [poster]. American Psychiatric Association Congress; 1999 May 15-20; Washington, DC
48.
Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20(5): 491–505PubMedCrossRef
49.
Keck Jr P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140(2): 173–84CrossRef
50.
Petit M, Raniwalla J, Tweed J, et al. Acomparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996; 32; 81–7PubMed
51.
Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry 1990; 147(4): 503–4PubMed
52.
Norris DL, Israelstam K. Clozapine (Leponex) overdosage [letter]. S Afr Med J 1975; 49: 385PubMed
53.
Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55Suppl. B: S157–S60
54.
Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 1996; 14: 111–23PubMedCrossRef
55.
Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19(1): 37–44PubMedCrossRef
56.
Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9(2): 99–107PubMedCrossRef
57.
Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997; 27(3): 313–23PubMedCrossRef
58.
Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997, 33(1): 155–9PubMed
59.
Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34(9): 1147–52PubMedCrossRef
60.
Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8(3): 151–9PubMedCrossRef
61.
McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36(5): 685–93PubMedCrossRef
62.
Szigethy E, Wiznitzer M, Branicky LA, et al. Risperidone-induced hepatotoxicity in children and adolescents? Achart review study. J Child Adolesc Psychopharmacol 1999; 9(2): 93–8PubMedCrossRef
63.
Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121–4PubMedCrossRef
64.
Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel group trial. Acta Psychiatr Scand 1995; 91: 271–7PubMedCrossRef
65.
Klieser E, Lehmann E, Kinzler E, et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15Suppl. 1: S45–S51CrossRef
66.
Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997; 11(1): 65–71PubMedCrossRef
67.
Wetterling T, Müssigbrodt H. Gewichtszunahme- eine Nebenwirkung von Nipolept (Zotepin)? Nervenarzt 1996; 67: 256–61PubMed
68.
Gopalaswamy AK, Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 258; 72: 254–8
69.
Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 1999; 60Suppl. 10: S15–S19
70.
71.
Leibowitz SF. The role of serotonin in eating disorders. Drugs 1990; 39Suppl. 3: S33–S48CrossRef
72.
Wurtman JJ, Wurtman RJ, Growdon JH, et al. Carbohydrate craving in obese people: suppression by treatments affecting serotoninergic transmission. Int J Eat Disord 1981; 1: 2–11CrossRef
73.
Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321–5PubMed
74.
Garattini S, Caccia S, Mennini T, et al. Biochemical pharmacology of the anorectic drug fenfluramine: a review. Curr Med Res Opin 1987; 1: 15–27
75.
Aulakh CS, Hill JL, Yoney HAT, et al. Evidence of involvement of 5-HT1c and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-iodophenyl)-2-amidopropane (DOI). Psychopharmacology 1992; 109: 444–8PubMedCrossRef
76.
Tecott LH, Sun M, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542–6PubMedCrossRef
77.
Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58(3): 108–11PubMedCrossRef
78.
Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83PubMedCrossRef
79.
Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60(11): 783–91PubMedCrossRef
80.
Hagg S, Joelson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294–9PubMedCrossRef
81.
Brömel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76–80PubMedCrossRef
82.
Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993–7PubMed
83.
George TP, Sernyak MJ, Ziedonis DM, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56(8): 344–6PubMed
84.
McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995; 37(8): 550–2PubMedCrossRef
85.
Jalenques I, Tauveron I, Albuisson E, et al. Weight gain as a predictor of long term clozapine efficiency. Clin Drug Invest 1996; 12: 16–25CrossRef
86.
Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 1999; 60(1): 41–4PubMedCrossRef
87.
Bapista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100: 3–16CrossRef
88.
Goodall E, Oxtoby C, Richards R, et al. Clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988; 153: 208–13PubMedCrossRef
89.
National Institute of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults — the evidence report. Obes Res 1998; 6 Suppl. 2: S51–S209
90.
Willett WC, Manson JE, Stampler MJ, et al. Weight, weight change, and coronary heart disease in women: risk within the ‘normal’weight range. JAMA 1995; 273: 461–5PubMedCrossRef
91.
Fenton WS, Blyler CF, Heinssen PK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637–51PubMedCrossRef
92.
Vestergaard P, Amidsen A, Schou M. Clinically significant side-effects of lithium treatment. Asurvey of 237 patients in long-term treatment. Acta Psychiat Scand 1980; 62: 193–200PubMedCrossRef
93.
Gaebel W. Towards the improvement of compliance: the significance of psycho-eduction and new antipsychotic drugs. Int Clin Psychopharmacol 1997; 12Suppl. 1: S537–S44
Metadata
Title
Bodyweight Gain with Atypical Antipsychotic
A Comparative Review
Author
Professor Tilman Wetterling
Publication date
01-01-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 1/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124010-00005

Other articles of this Issue 1/2001

Drug Safety 1/2001 Go to the issue

Review Article

Nephrotoxicity and Hepatotoxicity of Histamine H2 Receptor Antagonists

Review Article

NSAID-Induced Nephrotoxicity from the Fetus to the Child

Current Opinion

The Role of the Clinical Pharmacologist in the Management of Adverse Drug Reactions

Review Article

Anticancer Drug—Induced Kidney Disorders